Yeme Bozuklukları Sürdürüm Psikofarmakolojisi
Özet
Yeme bozukluklarının (YB) tedavisinde farmakoterapinin etkinliği üzerine odaklanan bu metin, Anoreksiya Nervoza (AN), Bulimiya Nervoza (BN) ve Tıkınırcasına Yeme Bozukluğu (TYB) gibi temel klinik tablolardaki ilaç yaklaşımlarını ele almaktadır. Çalışmalara göre farmakoterapi, yeme bozukluğunun temel semptomlarından ziyade tıbbi komplikasyonlar ve psikiyatrik komorbiditelerin yönetiminde daha etkilidir ve resmi onaylı ajanlar oldukça sınırlıdır. Antipsikotikler, özellikle olanzapin, AN hastalarında kilo alımı ve takıntılı düşünceleri azaltmada tercih edilirken; antidepresanlar, özellikle 60 mg/gün dozunda fluoksetin, BN'de tıkınırcasına yeme ve çıkarma ataklarını azaltmada FDA onaylı tek ilaç olarak öne çıkmaktadır. Ayrıca, antiepileptik bir ajan olan topiramatın ve stimülan sınıfından lisdexamfetaminin TYB semptomları ve kilo kontrolü üzerinde anlamlı başarı sağladığı gösterilmiştir. Hormonal tedaviler ve kanabinoid reseptör antagonistleri gibi alternatif yaklaşımlar da araştırılmaktadır. Sonuç olarak, psikotrop ilaçlar yeme bozukluklarında tek başına belirleyici olmamakla birlikte, özellikle psikoterapiye dirençli ve şiddetli komorbiditesi olan vakalarda klinik uygulamada değerli bir yardımcı rol oynamaktadır. Ancak kronikleşme eğilimi yüksek olan bu hastalık grubunda, sürdürüm tedavisinin etkinliğini ve net sürelerini belirlemek için daha uzun vadeli ve geniş örneklemli çalışmalara ihtiyaç duyulmaktadır.
The text, focusing on the efficacy of pharmacotherapy in treating eating disorders (ED), addresses drug approaches in primary clinical pictures such as Anorexia Nervosa (AN), Bulimia Nervosa (BN), and Binge Eating Disorder (BED). According to studies, pharmacotherapy is more effective in managing medical complications and psychiatric comorbidities rather than core ED symptoms, and officially approved agents remain strictly limited. While antipsychotics, particularly olanzapine, are preferred in AN patients to promote weight gain and reduce obsessive thoughts, antidepressants, especially fluoxetine at a dose of 60 mg/day, stand out as the only FDA-approved medication for reducing binge eating and purging episodes in BN. Additionally, the antiepileptic agent topiramate and the stimulant lisdexamfetamine have demonstrated significant success in controlling BED symptoms and weight. Alternative approaches, including hormonal therapies and cannabinoid receptor antagonists, are also being investigated. Consequently, while psychotropic drugs are not decisive on their own, they serve as valuable adjuncts in clinical practice, particularly for severe cases with psychiatric comorbidities or resistance to psychotherapy. However, given the high chronicity of these disorders, longer-term and larger-sample studies are required to determine the exact duration and efficacy of maintenance treatments.
Referanslar
Aigner M, Treasure J, Kaye W, Kasper S. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry 2011; 12(6): 400-43.
Himmerich H, Treasure J. Psychopharmacological advances in eating disorders. Expert Rev Clin Pharmacol 2018; 11(1): 95-108.
Hay PJ. Clinical psychopharmacology of eating disorder: A research update. Int J Neuropsychopharm 2012; 6: 1-14.
Treasure J, Claudino AM, Zucker N. Eating disorders. Lancet 2010; 375(9714): 583-93.
Flament MF, Bissada H, Spettigue W. Evidence-based pharmacotherapy of eating disorders. Int J Neuropsychopharmacol 2012; 15(2): 189-207.
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (DSM-5®): American Psychiatric Publishing.
Carr J, Kleiman SC, Bulik CM, Bulik-Sullivan EC, Carroll IM. Can attention to the intestinal microbiota improve understanding and treatment of anorexia nervosa? Expert Rev Gastroenterol Hepatol 2016; 10(5): 565-9.
Fazeli PK, Calder GL, Miller KK, et al. Psychotropic medication use in anorexia nervosa between 1997 and 2009. Int J Eat Disord 2012; 45(8): 970-6.
Hay P, Chinn D, Forbes D, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of eating disorders. Aust N Z J Psychiatry 2014; 48(11): 977-1008.
Smink FR, van Hoeken D, Hoek HW. Epidemiology, course, and outcome of eating disorders. Curr Opin Psychiatry. 2013; 26(6):543-8.
Milano W, Capasso A. Food behavior as risk factor for developing eating disorders. Integrative Food. Nutr Metab (Lond) 2017; 4(6): 1-9.
Halmi KA. Anorexia nervosa. In: Kaplan HI, Freedman AM, Sadock RJ, eds. Comprehensive textbook of psychiatry, vol 2, 3rd ed. Baltimore: Williams & Wilkins, 1980.
Hsu LKG. The treatment of anorexia nervosa. Am J Psychiatry 1986;143:573–581.
Russell GFM, Szmukler GI, Dare C. An evaluation of family therapy in anorexia nervosa and bulimia nervosa. Arch Gen Psychiatry 1987;44:1047–1056.
Eddy KT, Tabri N, Thomas JJ, et al. Recovery From Anorexia Nervosa and Bulimia Nervosa at 22-Year Follow-Up. J Clin Psychiatry 2017; 78(2):184-189.
Powers PS, Santana C. Available pharmacological treatments for anorexia nervosa. Expert Opin Pharmacother 2004; 5(11): 2287-92.
Powers PS. Pharmacotherapy for eating disorders and obesity childadolescs psychiatric. Clin N Am 2009; 18: 175-87.
Guido KW. Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa A case series. Int J Eat Disor 2015; 49(5): 529-33.
Trunko ME, Schwartz TA, Duvvuri V, Kaye WH. Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: Case reports. Int J Eat Disord 2011; 44(3): 269-75.
Hagman J, Gralla J, Sigel E, A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: A pilot study. J Am Acad Child Adolesc Psychiatry 2011; 50(9): 915-24
McElroy SL, Guerdjikova AI, Mori N, O’Melia AM. Current pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opin Pharmacother 2012; 13(14): 2015-26.
Mischoulon D, Eddy KT, Keshaviah A. Depression and eatingdisorders: Treatment and course. J Affect Disord 2011; 130(3): 470-7.
Claudino AM, Hay P, Lima MS, Bacaltchuk J, Schmidt U, Treasure J. Antidepressants for anorexia nervosa. Cochrane Database Syst Rev 2006; (1): CD004365.
Barbarich NC, McConaha CW, Halmi KA, et al. Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. Int J Eat Disord 2004; 35(1): 10-5.
Kaye WH. Neurobiology of anorexia nervosa purdue ingestive behavior research center symposium influences on eating and body weight over the lifespan Child. Adol Psysiol Behav 2008; 35: 121-35.
Safer DL, Darcy AM, Lock J. Use of mirtazapine in an adult with refractory anorexia nervosa and comorbid depression: A case report. Int J Eat Disord 2011; 44(2): 178-81.
Bacaltchuck J, Hay J. Antidepressants vs placebo for people with bulimia nervosa. Cochrane Database Syst Rev 2003; (1): CD003391.
Hay PJ, Claudino AC. Bulimia Nervosa. Clinical Evidence Review Update 2010; (7): 1009.
Milano W, Petrella C, Sabatino C, Capasso A. Treatment of bulimia nervosa with sertraline: A randomized controlled trial. Adv Ther 2004; 21(4): 232-7.
Milano W, Siano C, Putrella C, Capasso A, Capasso A. Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial. Adv Ther 2005; 22(3): 278-83. a
Milano W, Petrella C, Capasso A. Treatment of bulimia nervosa with citalopram: A randomized controlled trial. Biomed Res 2005; 16: 85-7. c
Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992; 49(2): 139-47.
Martiadis V, Castaldo E, Monteleone P, Maj M. The role of psychopharmacotherapy in the management of eating disorders. Clin Neuropsychiatry 2007; 4(2): 51-60.
Romano SJ, Halmi KA, Sarkar NP, Koke SC, Lee JS. A placebo controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry 2002; 159(1): 96-102.
Himmerich H, Benkert O. Medications for the treatment of eating disorders and obesity. Kompendium der Psychiatrischen Pharmakotherapie. 11th ed. Heidelberg (Germany): Springer; 2017. p. 778–796.
El-Giamal N, de Zwaan M, Bailer U, et al. Reboxetine in the treatment
Meister B. Neurotransmitters in key neurons of the hypothalamus that regulate feeding behavior and body weight. Physiol Behav 2007; 92(1-2): 263-71.
Gao Q, Horvath TL. Neuronal control of energy homeostasis. FEBS Lett 2008; 582(1): 132-41.
Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebocontrolled trial, part 2: Improvement in psychiatric measures. J Clin Psychiatry 2003; 64(12): 1449-54.
Nickel C, Tritt K, Muehlbacher M, Topiramate treatment in bulimia nervosa patients: A randomized, double-blind, placebocontrolled trial. Int J Eat Disord 2005; 38(4): 295-300.
McElroy SL, Hudson JI, Topiramato for treatment of binge eating disorder associated ad obesity: a placebo. Biol Psychiatry 2007; 61: 1039-48. a
Ricca V, Castellini G, Lo Sauro C, Rotella CM, Faravelli C. Zonisamide combinated with cognitive-behaviour therapy in binge eating disorder: one -year follow-up study. Psychiatry (Edgmont Pa) 2009; 6(11): 23-8.
McElroy SL, Guerdjikova A, Kotwal R, Atomoxetine in the treatment of binge eating disorder: A randomized placebo-controlled trial. J Clin Psychiatry 2007; 68(3): 390-8. B
Hill K, Bucuvalas J, McClain C, et al. Pilot study of growth hormone administration during the refeeding of malnourished anorexia nervosa patients. J Child Adolesc Psychopharmacol 2000; 10(1): 3-8.
Miller KK, Grieco KA, Klibanski A. Testosterone administration in women with anorexia nervosa. J Clin Endocrinol Metab 2005; 90(3): 1428-33
Stahl SM. Lisdexamfetamine. Prescriber’s guide: stahl’s essential psychopharmacology. 6th ed. Cambridge, United Kingdom: Cambridge University Press 2017; pp. 379-84.
Fornaro M, Solmi M, Perna G, et al. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. Neuropsychiatr Dis Treat. 2016;12: 1827–1836
Gasior M, Hudson J, Quintero J, Ferreira-Cornwell MC, Radewonuk J, McElroy SL. Multicenter, open-label, 12 month extension safety and tolerability trial of lisdexamphetamine dismelate in adults with binge eating disorder. J Clin Psychopharmacol 2017; 37(3): 315-22.
Badowski ME, Perez SE. Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS. HIV AIDS (Auckl) 2016; 8: 37-45.
Andries A, Frystyk J, Flyvbjerg A, Støving RK. Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial. Int J Eat Disord 2014; 47(1):18-23.
